Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
reembolso del 75% del coste de Búsquedas e Informes Tecnológicos de Patentes. Más información*
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
128
resultados
Última actualización
19/05/2024 [06:55:00]
Resumen de: WO2024102612A1
Provided herein is a high throughput screening method for compounds that modulate glucose transport into the brain. Also provided are compounds and drugs that can be used in the treatment of glucose transport related disorders. Additionally, an apparatus is disclosed that allows rapid screening of compounds and drugs in model animals.
Resumen de: WO2024102486A1
A method, system, and computer-readable medium are provided for an Automated Insulin Delivery (AID) system in which Model Predictive Control (MPC) thereof implements weighting of glucose target error relative to corresponding predicted blood glucose (BG) levels according to insulin on board (IOB). Accordingly, basal insulin infusion and available additional bolusing each in connection with glycemic disturbances such as unannounced meals can be proximally administered to maintain time in range (TIR) without incurring insulin stacking.
Resumen de: US2024161900A1
The present disclosure relates to systems and methods for controlling physiological glucose concentrations in a patient.
Resumen de: US2024158827A1
Embodiments of the invention provide amperometric analyte sensors having elements selected to optimize enzymatic activities associated with such sensors including polymers functionalized with enzymatic mediators as well as methods for making and using such sensors. While embodiments of the invention can be used in a variety of contexts, typical embodiments of the invention include glucose or ketone sensors used in the management of diabetes.
Resumen de: US2024156400A1
Systems, methods and/or devices for optimizing a patient's insulin dosage regimen over time, comprising at least a first memory for storing data inputs corresponding at least to one or more components in a patient's present insulin dosage regimen, and data inputs corresponding at least to the patient's blood-glucose-level measurements determined at a plurality of times, and a processor operatively connected to the at least first memory. The processor is programmed at least to determine from the data inputs corresponding to the patient's blood-glucose-level measurements determined at a plurality of times whether and by how much to vary at least one of the one or more components in the patient's present insulin dosage regimen. Also disclosed are systems, methods and/or devices for treating a patient's diabetes by providing treatment guidance, wherein the patient's current glycemic state is determined relative to a desired balance point; and determining from at least one of a plurality of the data corresponding to the patient's blood glucose-level measurements whether and by how much to vary at least one of the one or more components in the patient's present insulin dosage regimen to get closer to the patient's desired balance point; wherein the desired balance point is the patient's lowest blood glucose-level within a predetermined range achievable before increasing the frequency of hypoglycemic events above a predetermined threshold.
Resumen de: US2024156375A1
An application running on a device to manage insulin site rotation may read a configuration file including a group, a plurality of sites in the group, and an image associated with the group. The application may detect an input selecting a site from the plurality of sites for administration of an insulin management device. The application may also set the selected site as unavailable for a predetermined duration in response to the input selecting the site. A log entry may be written to track usage of the site in response to the input selecting the site. A visual indicator on the selected site may show that the site is recently selected in response to detecting the input selecting the site within a predetermined duration. The insulin management device may be a pump, a syringe, or a glucose monitor.
Resumen de: US2024156378A1
Devices are provided for measurement of an analyte concentration, e.g., glucose in a host. The device can include a sensor configured to generate a signal associated with a concentration of an analyte; and a sensing membrane located over the sensor. The sensing membrane comprises a diffusion resistance domain configured to control a flux of the analyte therethrough. The diffusion resistance domain comprises one or more zwitterionic compounds and a base polymer comprising both hydrophilic and hydrophobic regions.
Resumen de: US2024156373A1
The present invention relates to the technical field of blood glucose monitoring, and in particular to a split-type real-time blood glucose monitoring apparatus and a manufacturing method therefor. The real-time blood glucose monitoring apparatus comprises a sensor assembly and an emitter assembly. The sensor assembly comprises a first shell, and a conductive plating, a blood glucose sensor and a battery which are arranged on the first shell. The emitter assembly comprises a second shell and a circuit board in the second shell. The conductive plating is arranged on a shell wall of the first shell and is connected to the blood glucose sensor and the battery, and the conductive plating is provided with at least one first connecting structure; and the circuit board is provided with at least one second connecting structure. By means of the technical solution provided in the present invention, a sensor assembly can be further miniaturized by means of combining a conductive plating and a shell; and contacts for connection are arranged in a centralized manner, such that distribution points of the contacts for connection on the sensor assembly and the emitter assembly can be reduced, and the space occupied by a contact structure can be reduced, thereby facilitating the miniaturization of the product.
Resumen de: US2024156374A1
The present group of inventions refers to the medicine and medical technology and more particularly to methods and devices for monitoring blood glucose level by measuring the calorimetric method of the thermal effect and metabolic rate of the local area of living tissue. Method for monitoring blood glucose level is that the value of the thermal metabolism of the local area of living tissue of the effect or intensity of metabolism of the local area of living tissue is calculated as follows: at least one heat and waterproof applicator forming the closed system in the local area of tissue under the applicator is applied to the skin surface by a dosage pressure; temporal dynamics of physiological parameters of the local tissue region is measured under the applicator, in particular, at least the amount of water in the intercellular space of tissue under the applicator; temperature of a deep layer of tissue Tskin under the applicator; elastic pressure of tissue under the applicator. Temporal dynamics of climatic parameters of the environment, in particular, at least room temperature Troom and relative humidity of the air RHroom in the measurements room, as well as atmospheric pressure Patm are measured simultaneously or before the beginning of measurement of physiological parameters in the monitoring mode; the external heat flow through the enclosing structure is measured between the room and external environment or temperature of the external environment Text. Further, enthalpy of
Resumen de: US2024156376A1
An applicator assembly for applying at least a portion of an analyte monitor includes a frame having a longitudinal axis and an opening, a resilient member having at least a first portion fixed relative to the frame and a second portion movable axially relative to the frame, a needle, and a cap engageable with the frame to cover at least part of the opening. The cap is adjustable to increase a bias on the resilient member and to move the second portion of the resilient member away from the opening. When the cap is separated from the frame, the second portion of the resilient member is configured to be held relative to the frame. The hold on the second portion of the resilient member is releasable, such that the bias on the resilient member advances the second portion of the resilient member and the needle towards the opening.
Resumen de: US2024157052A1
Apparatuses and methods for transitioning to sleep mode or otherwise modified glucose target range in automated insulin delivery systems. For example, sleep mode can include a lower glucose target and/or lower and narrower glucose target range because of fewer variables that affect glucose values during sleep such as eating and exercise. Due to increased stability provided by the sleep mode target range, it is desirable to transition to the sleep mode target range as quickly as possible, while ensuring the transition is done safely and does not risk low glucose or hypoglycemia by too quickly switching to the lower and narrower target range. Systems and methods disclosed herein therefore provide various approaches for safely and quickly transitioning to sleep mode or other modified target ranges in order to improve time in range by being more aggressive to get to the lower sleep mode or other target faster without risking hypoglycemia.
Resumen de: US2024157053A1
Invasive glucose sensors and noninvasive glucose sensors may be used in conjunction to improve glucose management for a user. The rate of change (ROC) of glucose levels from a noninvasive glucose sensor may be used rather than or in conjunction with a glucose level of the user from a CGM. A basal insulin delivery rate to the user may be adjusted responsive to the ROC glucose level data from the noninvasive sensor. The glucose level ROC from a noninvasive glucose sensor may be used to predict future glucose level ROCs of the user between operational cycles of an insulin delivery device and/or to identify possible hypoglycemic or hyperglycemic events. These predicted future glucose level ROCs may be used in a cost function of the control system of the insulin delivery device to select basal insulin delivery doses. Glucose level readings may be used to calibrate a noninvasive glucose level sensor.
Resumen de: US2024157054A1
A method, system, and computer-readable medium are provided for an Automated Insulin Delivery (AID) system in which Model Predictive Control (MPC) thereof implements weighting of glucose target error relative to corresponding predicted blood glucose (BG) levels according to insulin on board (IOB). Accordingly, basal insulin infusion and available additional bolusing each in connection with glycemic disturbances such as unannounced meals can be proximally administered to maintain time in range (TIR) without incurring insulin stacking.
Resumen de: WO2024098905A1
Embodiments of the present application provide an exercise data processing method, a wearable device, a terminal, a body building device, and a medium. In the embodiments of the present application, by means of acquiring exercise data of a target user generated in an exercise process, a respiratory exchange ratio prediction module is used to predict the respiratory exchange ratio of the target user in the exercise process; and on the basis of the respiratory exchange ratio and a corresponding relationship between the respiratory exchange ratio and a sugar-to-fat ratio, how many of calories consumed in a user's exercise are from fat consumption can be accurately determined, the accuracy of calorie calculation in the exercise process is improved, the real calorie consumption condition of the target user is reflected, the precise fat reduction perception experience of the target user is improved, and the entire process does not require a large amount of experiential data signal processing operations, such that the method further has the advantages of high efficiency and rapidness.
Resumen de: AU2024202804A1
Methods and apparatus, including computer program products, are provided for backfilling. In some example embodiments, there is provided a method that includes receiving, at a receiver, backfill data representative of sensor data stored, at a continuous blood glucose sensor and transmitter assembly, due to a loss of a wireless link between the receiver and the continuous blood glucose sensor and transmitter assembly; generating, at the receiver, at least one of a notification or a graphically distinct indicator for presentation at a display of the receiver, the at least one of the notification or the graphically distinct indicator enabling the backfill data to be graphically distinguished, when presented at the display, from non-backfill data; and generating, at the receiver, a view including the backfill data, the non-backfill data, and the generated at least one of the notification or the graphically distinct indicator. Related systems, methods, and articles of manufacture are also described.
Resumen de: AU2022401221A1
The present invention relates to a method for predicting a biometric value in a blood glucose measurement system and, more particularly, to a biometric value prediction method capable of predicting a future biometric value of a user by generating a predictive model through a communication terminal having a small memory and amount of calculations, such as a smartphone that the user always carries to manage a biometric value, and applying the biometric value of the user to the generated predictive model, and capable of predicting a future biometric value of the user without requiring biometric information of other nearby users and without access to a server, by generating a predictive model personalized for the user on the basis of biometric history information of the user.
Resumen de: US2024157056A1
In some embodiments, an adjunct device for tracks time and/or dosage of a medicine. The device may include a connector for mounting the device to a deposable pen injector. The device may be configured to allow use of the native controls and injectors of the injector. For example the device may include a view port for viewing a dose indicator of the injector. The device may include one or more vibration sensors. A processor may be configured to differentiate increasing a dose, decreasing a dose and/or discharging the medicine based on the output of the sensors. Optionally a display of the device may be positioned for simultaneous viewing with the dosage indicator of the injector. For example a user may verify the accuracy of the adjunct device before performing a discharge.
Resumen de: US2024157055A1
A drug delivery system including a memory storing programming code operable to enable delivery of insulin and a processor operable to execute the programming code. When executed, the programming code causes the processor to: calculate a first aggregate insulin-on-board amount for a user based on a plurality of individual insulin-on-board estimates made over a first period of time, determine that the first aggregate insulin-on-board amount is greater than a maximum depot formation threshold amount, determine a first residual amount of insulin remaining in the first aggregate insulin-on-board amount, increase a subsequent calculation of an individual insulin-on-board estimate based on the first residual amount of insulin, and utilize the subsequent calculation of the individual insulin-on-board estimate in a calculation of a second aggregate insulin-on-board amount over a second period of time.
Resumen de: WO2024097820A1
Embodiments can relate to a system for automatically detecting sensor compression in continuous glucose monitoring including at least one sensor and at least one processor in communication with the at least one sensor, the at least one processor executing at least two machine learning models, wherein the at least one processor is programmed or configured to cause the processor to receive, from the at least one sensor, measurement data including at least one time series of blood glucose (BG) measurements measured by the at least one sensor, determine that the at least one time series of BG measurements is a candidate series including a compression artifact using a first machine learning model, and generate, using a second machine learning model, a signal output indicating that the at least one time series of BG measurements was obtained while the at least one sensor was subject to compression.
Resumen de: WO2024097378A1
Exemplary embodiments may provide an on-body medicament delivery system that provides basal delivery of a medicament to a type 2 diabetes patient and that automatically performs medicament titration for the patient. The medicament delivery system performs medicament titration based on glucose level readings for the patient. These glucose levels may be provided wirelessly from a glucose sensor, such as a continuous glucose monitor, or may be entered manually by the patient into a management device, such as a smartphone running an application that provides a user interface for the patient to enter the glucose level readings. The medicament delivery system adjusts the basal medicament delivery rate/dose based on the glucose level readings for the patient. The adjustments may be performed by a programmatic mechanism, such as by computer programming instructions executing on a processor.
Resumen de: WO2024097207A1
Invasive glucose sensors and noninvasive glucose sensors may be used in conjunction to improve glucose management for a user. The rate of change (ROC) of glucose levels from a noninvasive glucose sensor may be used rather than or in conjunction with a glucose level of the user from a CGM. A basal insulin delivery rate to the user may be adjusted responsive to the ROC glucose level data from the noninvasive sensor. The glucose level ROC from a noninvasive glucose sensor may be used to predict future glucose level ROCs of the user between operational cycles of an insulin delivery device and/or to identify possible hypoglycemic or hyperglycemic events. These predicted future glucose level ROCs may be used in a cost function of the control system of the insulin delivery device to select basal insulin delivery doses. Glucose level readings may be used to calibrate a noninvasive glucose level sensor.
Resumen de: WO2024096007A1
The purpose of the present invention is to provide: an inhibitor of glucose uptake into red blood cells; and a blood-collecting tube which suppresses glucose concentration reduction. The present invention provides an inhibitor of glucose uptake into red blood cells, the inhibitor containing inosine as an active ingredient. The inhibitor according to the present invention can be used to suppress a reduction in the glucose concentration in the whole blood collected in a blood-collecting tube. Moreover, the present invention provides a blood-collecting tube including inosine in the internal space thereof. The blood-collecting tube according to the present invention can be used to measure the glucose concentration in the blood. The blood-collecting tube according to the present invention may further include a glycolytic inhibitor.
Resumen de: US2024148972A1
Disclosed herein are apparatuses and methods that account for meal announcements in closed loop insulin delivery systems. Rather than simply increasing an insulin delivery rate in response to the meal announcement, the closed loop algorithm can be modified to increase the insulin on board tolerance during eating periods. This approach utilizes the stability of the cascaded loop in the closed loop algorithm to prevent the oscillations in glucose levels that can occur by simply increasing the basal rate.
Resumen de: US2024148283A1
The present disclosure related to an apparatus that may be used for taking blood glucose measurements and providing individualized insulin dose recommendations wherein the apparatus is easy to use and facilitates improved diabetes control in patients. Also disclosed are related methods.
Nº publicación: US2024148259A1 09/05/2024
Solicitante:
MEDTRONIC INC [US]
Medtronic, Inc
Resumen de: US2024148259A1
A medical system including processing circuitry configured to receive a cardiac signal indicative of a cardiac characteristic of a patient from sensing circuitry and configured to receive a glucose signal indicative of a glucose level of the patient. The processing circuitry is configured to formulate a training data set including one or more training input vectors using the cardiac signal and one or more training output vectors using the glucose signal. The processing circuitry is configured to train a machine learning algorithm using the formulated training data set. The processing circuitry is configured to receive a current cardiac signal from the patient and determine a representative glucose level using the current cardiac signal and the trained machine learning algorithm.
BOPI
Sede Electrónica
